Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 4Adenocarcinoma Of Esophagus 3Stomach Neoplasms 2Esophageal Neoplasms 2Adenocarcinoma 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Desmoplastic Small Round Cell Tumor 1

Interventions

Oxaliplatin 8Fluorouracil 8pembrolizumab 7Paclitaxel 6Trastuzumab 5Leucovorin 5Capecitabine 5Specimen Handling 4Radiation 4Cisplatin 4Carboplatin 4tislelizumab 3patritumab deruxtecan 3Taxes 3Radiotherapy 3Nivolumab 3ulixertinib 2trastuzumab deruxtecan 2trastuzumab biosimilar HLX02 2durvalumab 2Surgical Procedures, Operative 2Ramucirumab 2Pemetrexed 2PF-05280014 2Ontruzant 2Ogivri 2Magnetic Resonance Spectroscopy 2Irinotecan 2Immunotherapy 2Exercise 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Esophageal Neoplasms × Ramucirumab × 30 days × Clear all
NCT06251973 2026-05-15

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
20 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT06445972 2026-05-12

MK-3475-06D

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
210 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡